ADGI ADAGIO THERAPEUTICS INC

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Wednesday, August 14, 2024, at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent business highlights.

Listeners can register for the webcast via this . Analysts wishing to participate in the question and answer session should use this . A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit / to learn more.

Contacts:

Media Relations

(781) 208-1747

Investor Relations

(781) 208-1747



EN
12/08/2024

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Str...

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) Independent evaluation of KP.3.1.1 and LB.1 variants shows in vitro pseudovirus neutralization potency of PEMGARDA in-line with prior variants testedProprietary, ongoing SARS-CoV-2 spike analyses demonstrate consistent structural stability of the pemivibart binding site to date, which has routinely predicted sustained pemivibart in vitro neutralization activity Potential emerging variants, such as XEC and LP.1, encode mutations that ...

2h / 23m 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGAR...

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised patients at greatest risk for serious infections or even death due to COVID-19 PEMGARDA™ available under Emergency Use Authorization (EUA) for certain immunocompromised adults and adolescents; recommended by Infectious Disease Society of Americas (IDSA) guidelinesCovered by Medicare and Medicaid an...

September 12, 2024 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside Chat Date: Friday, September 6, 2024Fireside Chat Time: 10:00 AM ETLocation: New York, NY H.C. Wainwright 26th Annual Global Investment ConferenceFireside Chat Date: Monday, September 9, 2024Fireside Chat Time: 9:30...

September 5, 2024 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311,...

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) --  Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, a next generation monoclonal antibody (mAb) candidate for COVID-19. VYD2311 is a mAb with high in vitro neutralization potency shown ...

September 4, 2024 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivi...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants testedCenter for Disease Control reports KP.3.1.1 is the only major variant increasing in proportionality nationallyVariants confirmed as susceptible to pemivibart in independent analyses contain key Q493E, s31del, and other mutations that are prominent in circulating SAR...

September 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch